Increased mutational frequency of KDM6A, in addition to high expression of PPARG, may drive more aggressive, higher-stage bladder tumors in female-gender patients, whereas frequent mutations in TP53 may contribute to increased incidence of bladder cancer in male-gender patients. Here, KDM6A is linked to urinary bladder cancer.